651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II

In Vivo postnatal loss of mature osteoblasts creates an immunosuppressive bone marrow microenvironment to permit the engraftment and proliferation of myeloma cells

Impact of the stromal microenvironment on the extrinsic apoptotic pathway in multiple myeloma

Immune aging and macrophage inhibitory factor MIF – mediated stromal rewiring drives pre malignant evolution in smoldering multiple myeloma

RXR agonist IRX4204 induces ferroptosis in multiple myeloma via HMOX1 GPX4 axis and enhances lenalidomide efficacy

Diagnosis and prediction of precursor states in multiple myeloma using cell free chromatin

RXR agonist IRX4204 enhances BCMA CAR T cell efficacy by suppressing ferroptosis via CHAC1 downregulation

Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti BCMA CAR T therapy for multiple myeloma

Disruption of NEAT1 transcriptional network identifies targetable non genetic dependencies in multiple myeloma

DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma

A human IL 6–Expressing PDX model of multiple myeloma recapitulates clinical features and supports patient derived tumor engraftment

Recurrent loss of chromosome y in multiple myeloma is linked to disease progression and altered tumor immune microenvironment

Single cell transcriptomics reveals proliferative immune evasive and bone marrow–independent transcriptional programs in extramedullary multiple myeloma

Cyclin D1 beyond the cell cycle A new role in t 11 14 multiple myeloma

An acquired immune metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed high risk multiple myeloma

Development of novel small molecule DDX5 inhibitors for treating relapsed and or refractory multiple myeloma

IFN α potentiates daratumumab response in multiple myeloma A commpass study

Accelerated immune aging after induction therapy in multiple myeloma revealed by donor referenced immune age modeling

Single cell immune landscape associated with isatuximab carfilzomib lenalidomide and dexamethasone induction efficacy in newly diagnosed myeloma

Integrated transcriptomic and proteomic analysis of clonal plasma cells from patients with AL amyloidosis

Single cell transcriptomics reveals pathogenic interactions between clonal plasma cells and monocytes in POEMS syndrome

Multiomic evidence of coordinated complex rearrangements enhancer hijacking and epigenomic signatures in the first whole chromosome phased myeloma genomes

Biology of circulating tumor cells CTCs in multiple myeloma MM Comparative transcriptomic profiling reveals egression associated changes related to CTC burden

Semaphorin 4D and interleukin 1beta complement cascade axis are key drivers of disease progression in multiple myeloma

Enhancing immunotherapy efficacy in myeloma with a novel dual action mitochondrial toxic peptide that overcomes resistance and induces immunogenic cell death

Single cell transcriptomics of AL amyloidosis reveals pathogenic mechanisms immune interactions and altered clonal and polyclonal plasma cell phenotypes

Whole genome sequencing of cell free DNA for assessment of minimal residual disease in high risk smoldering multiple myeloma

Monoclonal and polyclonal circulating plasma cells CPCs are linked to disease spread in multiple myeloma

Improve therapeutic response through inhibition of endosome machinery in multiple myeloma

Impact of prior BCMA targeted therapy on CAR T expansion and host T cell phenotypes in patients with Relapsed Refractory multiple myeloma receiving BCMA CAR T therapy

Long read direct RNA seq reveals dynamic MM transcriptome made of novel isoforms and post transcriptional modifications

Phenotypic evolution of circulating tumor plasma cells across MGUS SMM and multiple myeloma